Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
SUDAFED 24 HOUR vs ADVIL CONGESTION RELIEF
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Pseudoephedrine is a sympathomimetic amine that acts as a decongestant by stimulating alpha-adrenergic receptors in the respiratory tract mucosa, causing vasoconstriction and reducing nasal congestion.
ibuprofen: non-selective COX-1/COX-2 inhibitor reducing prostaglandin synthesis; phenylephrine: alpha-1 adrenergic receptor agonist causing vasoconstriction
Relief of nasal congestion associated with common cold, hay fever, and other upper respiratory allergies,Off-label: Eustachian tube congestion
temporary relief of nasal congestion,sinus pressure,headache,fever,minor aches and pains associated with common cold or flu
120 mg orally every 24 hours (extended-release tablet).
1 tablet (ibuprofen 200 mg / phenylephrine 10 mg) orally every 4 hours while symptoms persist, not to exceed 6 tablets in 24 hours.
Terminal elimination half-life 9-16 hours (mean 11 hours) in adults; prolonged in renal impairment (up to 24-30 hours in severe insufficiency); clinically relevant for dosing interval (every 24 hours)
Ibuprofen: 2-4 hours (short half-life requires frequent dosing). Pseudoephedrine: 5-8 hours (longer in alkaline urine). Context: Half-life prolonged in renal impairment.
Primarily hepatic via N-demethylation to active metabolite (norpseudoephedrine); also undergoes oxidative metabolism. CYP450 enzymes involved include CYP2D6.
ibuprofen: primarily hepatic via CYP2C9; phenylephrine: primarily hepatic via monoamine oxidase (MAO) and sulfation
Renal 70-90% unchanged; minor hepatic metabolism to inactive metabolites; biliary/fecal excretion negligible (<5%)
Renal: ~90% as unchanged drug and metabolites (ibuprofen: <10% unchanged, pseudoephedrine: 43-96% unchanged). Biliary/fecal: minimal (<5%).
Low, approximately 20-30%; primarily binds to albumin
Ibuprofen: >99% bound to albumin. Pseudoephedrine: 20-30% bound to albumin.
2.6-3.5 L/kg; suggests extensive tissue distribution (highly lipophilic)
Ibuprofen: 0.1-0.2 L/kg (low, reflects high protein binding). Pseudoephedrine: 2.6-3.5 L/kg (extensive tissue distribution).
Oral: 100% (well absorbed); extended-release formulation designed for once-daily dosing
Oral: Ibuprofen ~80-100% (high), Pseudoephedrine ~100% (high).
GFR 30-50 m L/min: 120 mg every 24 hours; GFR <30 m L/min: not recommended.
Avoid use if Cr Cl <30 m L/min. For Cr Cl 30-59 m L/min, use lowest effective dose and shortest duration.
No adjustment necessary; monitor for adverse effects in Child-Pugh C.
Avoid use in severe hepatic impairment (Child-Pugh class C). For moderate impairment (Child-Pugh class B), use with caution and at the lowest effective dose.
Children 6-11 years: 60 mg orally every 24 hours (extended-release tablet).
Not recommended in children under 12 years of age due to phenylephrine component. For children 12 years and older, same as adult dosing.
Start with 60 mg orally every 24 hours; increase gradually based on response and tolerability.
Start at the low end of dosing range; avoid use in patients 65 years and older if possible due to increased risk of adverse effects; if necessary, use lowest effective dose for shortest duration.
None.
ibuprofen carries a black box warning for increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal, and for serious gastrointestinal adverse events including bleeding, ulceration, and perforation of the stomach or intestines
May cause hypertension, palpitations, tachycardia, arrhythmias, and stroke; use with caution in patients with cardiovascular disease, hypertension, hyperthyroidism, diabetes, or prostatic hypertrophy; avoid in patients with severe hypertension or coronary artery disease; risk of drug dependence with long-term use; avoid use with MAOIs or within 14 days of MAOI therapy.
cardiovascular risk,gastrointestinal risk,renal effects,avoid concomitant use of other NSAIDs,hypertension,hyperthyroidism,diabetes,heart disease,use with MAOIs may cause hypertensive crisis
Severe hypertension, coronary artery disease, narrow-angle glaucoma, urinary retention, concurrent MAOI therapy or within 14 days, hypersensitivity to pseudoephedrine.
hypersensitivity to ibuprofen, phenylephrine, or any component,history of asthma, urticaria, or allergic-type reactions to aspirin or other NSAIDs,perioperative pain in setting of coronary artery bypass graft (CABG) surgery,severe hypertension,severe coronary artery disease,use of MAOIs or within 14 days of stopping MAOIs
Avoid high-tyramine foods (e.g., aged cheeses, cured meats, soy products) if taking MAOIs. Caffeine may increase stimulant effects. Alcohol may exacerbate CNS side effects.
Avoid alcohol consumption due to increased risk of GI bleeding and liver damage. No specific food interactions; take with food or milk to reduce stomach upset. Caffeine may exacerbate pseudoephedrine's stimulant effects; limit caffeine intake.
First trimester: No evidence of major malformations in human studies. Second and third trimesters: Potential for uterine vasoconstriction and reduced placental perfusion; may cause fetal tachycardia or arrhythmias. Use only if benefit outweighs risk.
First trimester: Avoid due to potential increased risk of cardiac defects and gastroschisis from NSAIDs. Second trimester: Use with caution; ibuprofen may cause oligohydramnios and premature ductus arteriosus constriction. Third trimester: Contraindicated due to risk of premature closure of ductus arteriosus, oligohydramnios, and neonatal renal impairment. Phenylephrine: Limited human data; animal studies show fetal abnormalities at high doses; avoid in first trimester due to potential vascular disruption.
Pseudoephedrine is excreted in breast milk (M/P ratio ~3.3). May reduce milk production. Use with caution; monitor infant for irritability and sleep disturbances.
Ibuprofen: Excreted into breast milk in low amounts (M/P ratio ~0.07). Compatible with breastfeeding; minimal infant exposure. Phenylephrine: Not known if excreted in breast milk; M/P ratio unknown. Avoid due to potential for infant hypertension and irritability. Alternative decongestants preferred.
No specific dose adjustment recommended. However, decreased gastrointestinal motility and increased plasma volume in pregnancy may alter absorption and distribution; use lowest effective dose for shortest duration.
Pharmacokinetic changes in pregnancy: Increased volume of distribution and clearance for ibuprofen may require higher doses, but avoid due to fetal risks. No standard dose adjustment recommended; use lowest effective dose for shortest duration. Phenylephrine: No specific dosing adjustments in pregnancy; avoid use due to limited safety data.
Contains pseudoephedrine HCl 240 mg extended-release. Contraindicated in severe hypertension, coronary artery disease, and MAOI use. Avoid alcohol; may cause insomnia, anxiety, or tachycardia. Advise against bedtime dosing.
Advil Congestion Relief combines ibuprofen (NSAID) and pseudoephedrine (decongestant). Ibuprofen can cause nephrotoxicity; pseudoephedrine can elevate blood pressure and heart rate. Avoid in patients with uncontrolled hypertension, severe CAD, or MAOI use within 14 days. Use with caution in elderly due to increased risk of GI bleeding and CNS effects. Not recommended for children under 12 years.
Do not crush or chew the tablet; swallow whole with water.,Do not take more than one tablet in 24 hours.,Avoid other products containing pseudoephedrine or other decongestants.,Discontinue if you experience palpitations, chest pain, or dizziness.,Consult a doctor before use if you have high blood pressure, heart disease, diabetes, or glaucoma.
Do not take more than directed; do not use with other products containing ibuprofen or other NSAIDs (e.g., naproxen, aspirin) due to increased risk of stomach bleeding.,Avoid alcohol while taking this medication to reduce the risk of stomach irritation and bleeding.,Pseudoephedrine may cause insomnia, nervousness, or dizziness; take the last dose at least 4-6 hours before bedtime.,Stop use and consult a doctor if symptoms persist after 5 days (fever >3 days), if new symptoms appear, or if you experience signs of stomach bleeding (black/bloody stools, vomit with blood/coffee-grounds).,Do not use if you have heart disease, high blood pressure, thyroid disease, diabetes, glaucoma, or difficulty urinating due to an enlarged prostate unless directed by a doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about SUDAFED 24 HOUR vs ADVIL CONGESTION RELIEF, answered by our medical review team.
SUDAFED 24 HOUR is a Decongestant that works by Pseudoephedrine is a sympathomimetic amine that acts as a decongestant by stimulating alpha-adrenergic receptors in the respiratory tract mucosa, causing vasoconstriction and reducing nasal congestion.. ADVIL CONGESTION RELIEF is a NSAID/Decongestant Combination that works by ibuprofen: non-selective COX-1/COX-2 inhibitor reducing prostaglandin synthesis; phenylephrine: alpha-1 adrenergic receptor agonist causing vasoconstriction. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between SUDAFED 24 HOUR and ADVIL CONGESTION RELIEF depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of SUDAFED 24 HOUR is: 120 mg orally every 24 hours (extended-release tablet).. The standard adult dose of ADVIL CONGESTION RELIEF is: 1 tablet (ibuprofen 200 mg / phenylephrine 10 mg) orally every 4 hours while symptoms persist, not to exceed 6 tablets in 24 hours.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between SUDAFED 24 HOUR and ADVIL CONGESTION RELIEF in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. SUDAFED 24 HOUR is classified as Category C. First trimester: No evidence of major malformations in human studies. Second and third trimesters: Potential for uterine vasoconstriction and reduced placental perfusion; may cause. ADVIL CONGESTION RELIEF is classified as Category C. First trimester: Avoid due to potential increased risk of cardiac defects and gastroschisis from NSAIDs. Second trimester: Use with caution; ibuprofen may cause oligohydramnios and. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.